Pharmacoepidemiology and drug safety
-
Pharmacoepidemiol Drug Saf · Jan 2000
A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals.
To determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals. In addition, to determine predictors of peripheral neuropathy occurrence in HIV-1 infected individuals who are on a ddI- and/or d4T-containing antiretroviral drug regimen. ⋯ These findings suggest that hydroxyurea augmentation of a ddI- and/or d4T-containing antiretroviral drug regimen may increase the risk of peripheral neuropathy occurrence in HIV-1 infected patients. Copyright (c) 2000 John Wiley & Sons, Ltd.